{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:48Z","timestamp":1786980108381,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007380","name":"Fondation de l'Avenir pour la Recherche M\u00e9dicale Appliqu\u00e9e","doi-asserted-by":"publisher","award":["ANR-10-IAHU-02"],"award-info":[{"award-number":["ANR-10-IAHU-02"]}],"id":[{"id":"10.13039\/100007380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PIPAC is a recent approach for intraperitoneal chemotherapy with promising results for patients with peritoneal carcinomatosis. A systematic review was conducted to assess current evidence on the efficacy and outcomes of PIPAC in patients affected by ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study adhered to the PRISMA guidelines. PubMed, Google Scholar and ClinicalTrials.gov were searched up to December 2023. Studies reporting data on patients with OC treated with PIPAC were included in the qualitative analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one studies and six clinical trials with 932 patients who underwent PIPAC treatment were identified. The reported first access failure was 4.9%. 89.8% of patients underwent one, 60.7% two and 40% received three or more PIPAC cycles. Pathological tumour response was objectivated in 13 studies. Intra-operative complications were reported in 11% of women and post-operative events in 11.5% with a 0.82% of procedure-related mortality. Quality of life scores have been consistently stable or improved during the treatment time. The percentage of OC patients who became amenable for cytoreductive surgery due to the good response after PIPAC treatment for palliative purposes is reported to be 2.3%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results showed that PIPAC is safe and effective for palliative purposes, with a good pathological tumour response and quality of life. Future prospective studies would be needed to explore the role of this treatment in different stages of the disease, investigating a paradigm shift towards the use of PIPAC with curative intent for women who are not eligible for primary cytoreductive surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-024-07586-z","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T13:01:49Z","timestamp":1718456509000},"page":"1845-1856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in ovarian cancer: a systematic review of current evidence"],"prefix":"10.1007","volume":"310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-9464","authenticated-orcid":false,"given":"Matteo","family":"Pavone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Jochum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Lecointre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bizzarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Taliento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Restaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Querleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherif","family":"Akladios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"1","key":"7586_CR1","first-page":"99","volume":"38","author":"F Bray","year":"2002","unstructured":"Bray F, Sankila R, Ferlay J, Parkin DM (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer Oxf Engl 1990 38(1):99\u2013166","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"7586_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ygyno.2021.07.025","volume":"163","author":"C Marchetti","year":"2021","unstructured":"Marchetti C, Rosati A, De Felice F, Boccia SM, Vertechy L, Pavone M et al (2021) Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: a propensity-score matching analysis. Gynecol Oncol 163(1):29\u201335","journal-title":"Gynecol Oncol"},{"issue":"1","key":"7586_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.52054\/FVVO.15.1.060","volume":"15","author":"V Ghirardi","year":"2023","unstructured":"Ghirardi V, Fagotti A, Scambia G (2023) Laparoscopic selection for surgery in epithelial ovarian cancer. a short review. Facts Views Vis ObGyn 15(1):25\u201328","journal-title":"Facts Views Vis ObGyn"},{"issue":"9","key":"7586_CR4","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18(9):1274\u20131284","journal-title":"Lancet Oncol"},{"issue":"15","key":"7586_CR5","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"A Du Bois","year":"2017","unstructured":"Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol 35(15):5501\u20135501","journal-title":"J Clin Oncol"},{"issue":"10","key":"7586_CR6","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 23(10):2605\u20132612","journal-title":"Ann Oncol"},{"issue":"23","key":"7586_CR7","first-page":"00082","volume":"S0007\u20134551","author":"V Ghirardi","year":"2023","unstructured":"Ghirardi V, Trozzi R, Scambia G, Fagotti A (2023) Current and future trials about HIPEC in ovarian cancer. Bull Cancer (Paris) S0007\u20134551(23):00082\u201300086","journal-title":"Bull Cancer (Paris)"},{"issue":"4","key":"7586_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.23736\/S0026-4806.19.06081-6","volume":"110","author":"A Di Giorgio","year":"2019","unstructured":"Di Giorgio A, Abatini C, Attalla El Halabieh M, Vita E, Vizzielli G, Gallotta V et al (2019) From palliation to cure: PIPAC for peritoneal malignancies. Minerva Med 110(4):385\u2013398","journal-title":"Minerva Med"},{"issue":"3","key":"7586_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230\u2013240","journal-title":"N Engl J Med"},{"issue":"9","key":"7586_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.gyobfe.2013.07.011","volume":"41","author":"E Furet","year":"2013","unstructured":"Furet E, Ch\u00e9reau E, Lambaudie E, Bannier M, Houvenaeghel G (2013) Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer. Gynecol Obstet Fertil 41(9):493\u2013498","journal-title":"Gynecol Obstet Fertil"},{"issue":"6","key":"7586_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","volume":"30","author":"S Koole","year":"2020","unstructured":"Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D et al (2020) Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer 30(6):888\u2013892","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"7586_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13304-018-0600-y","volume":"71","author":"S Cianci","year":"2019","unstructured":"Cianci S, Ronsini C, Vizzielli G, Tropea A, Biondi A, Scambia G et al (2019) Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. Updat Surg 71(2):389\u2013394","journal-title":"Updat Surg"},{"issue":"2","key":"7586_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C et al (2014) Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21(2):553\u2013559","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"7586_CR14","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJP, Osma A, Kabakci B, Diaz-Carballo D et al (2016) Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol 142(11):2275\u20132280","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"7586_CR15","first-page":"1102","volume":"43","author":"M H\u00fcbner","year":"2017","unstructured":"H\u00fcbner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N (2017) Pressurized intraperitoneal aerosol chemotherapy\u2014practical aspects. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 43(6):1102\u20131109","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"7","key":"7586_CR16","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","volume":"20","author":"A Blanco","year":"2013","unstructured":"Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA (2013) Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 20(7):2311\u20132316","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"7586_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/bjs.10521","volume":"104","author":"F Grass","year":"2017","unstructured":"Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, H\u00fcbner M (2017) Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 104(6):669\u2013678","journal-title":"Br J Surg"},{"issue":"7","key":"7586_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"9","key":"7586_CR19","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9):dju244","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"7586_CR20","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.3802\/jgo.2018.29.e47","volume":"29","author":"AA Elzarkaa","year":"2018","unstructured":"Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E et al (2018) Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol 29(4):e47","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"7586_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"7586_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/pp-2016-0011","volume":"1","author":"W Solass","year":"2016","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F (2016) Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum 1(2):99\u2013107","journal-title":"Pleura Peritoneum"},{"issue":"5","key":"7586_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"7586_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271\u2013292","journal-title":"J Health Econ"},{"issue":"2","key":"7586_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","volume":"137","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J et al (2015) Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 137(2):223\u2013228","journal-title":"Gynecol Oncol"},{"issue":"23\u201324","key":"7586_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10354-014-0312-y","volume":"164","author":"CB Tempfer","year":"2014","unstructured":"Tempfer CB, Solass W, Reymond MA (2014) Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review. Wien Med Wochenschr 164(23\u201324):519\u2013528","journal-title":"Wien Med Wochenschr"},{"issue":"4","key":"7586_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.mehy.2015.07.001","volume":"85","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB (2015) Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis. Med Hypotheses 85(4):480\u2013484","journal-title":"Med Hypotheses"},{"issue":"1","key":"7586_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12885-016-3004-8","volume":"17","author":"CB Tempfer","year":"2017","unstructured":"Tempfer CB, Hartmann F, Hilal Z, Rezniczek GA (2017) Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report. BMC Cancer 17(1):26","journal-title":"BMC Cancer"},{"issue":"4","key":"7586_CR29","first-page":"2309","volume":"35","author":"U Giger-Pabst","year":"2015","unstructured":"Giger-Pabst U, Solass W, Buerkle B, Reymond MA, Tempfer CB (2015) Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient. Anticancer Res 35(4):2309\u20132314","journal-title":"Anticancer Res"},{"issue":"1","key":"7586_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","volume":"150","author":"CB Tempfer","year":"2018","unstructured":"Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA (2018) A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 150(1):23\u201330","journal-title":"Gynecol Oncol"},{"issue":"10","key":"7586_CR31","first-page":"1379","volume":"41","author":"K Odendahl","year":"2015","unstructured":"Odendahl K, Solass W, Demtr\u00f6der C, Giger-Pabst U, Zieren J, Tempfer C et al (2015) Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 41(10):1379\u20131385","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"2","key":"7586_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40944-018-0193-x","volume":"16","author":"SP Somashekhar","year":"2018","unstructured":"Somashekhar SP, Rajagopal AK, Zaveri SS, Chandrashekhar RK, Rauthan A, Rakshit SH (2018) First Indian study on pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedure for advanced peritoneal carcinomatosis secondary to epithelial ovarian cancer. Indian J Gynecol Oncol 16(2):25","journal-title":"Indian J Gynecol Oncol"},{"key":"7586_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4596176","volume":"2017","author":"H Teixeira Farinha","year":"2017","unstructured":"Teixeira Farinha H, Grass F, Kefleyesus A, Achtari C, Romain B, Montemurro M et al (2017) Impact of pressurized intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract 2017:1\u201310","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"7586_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"14","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M, De Simone M (2016) Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol 14(1):128","journal-title":"World J Surg Oncol"},{"issue":"11","key":"7586_CR35","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","volume":"43","author":"M Alyami","year":"2017","unstructured":"Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D et al (2017) Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol 43(11):2178\u20132183","journal-title":"Eur J Surg Oncol"},{"issue":"2018","key":"7586_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2743985","volume":"24","author":"F Kurtz","year":"2018","unstructured":"Kurtz F, Struller F, Horvath P, Solass W, B\u00f6sm\u00fcller H, K\u00f6nigsrainer A et al (2018) Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroenterol Res Pract 24(2018):1\u20138","journal-title":"Gastroenterol Res Pract"},{"issue":"12","key":"7586_CR37","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.21873\/anticanres.13062","volume":"38","author":"V Larbre","year":"2018","unstructured":"Larbre V, Alyami M, Mercier F, Vantard N, Bonnefoy I, Opsomer MA et al (2018) No renal toxicity after repeated treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with unresectable peritoneal metastasis. Anticancer Res 38(12):6869\u20136875","journal-title":"Anticancer Res"},{"issue":"1","key":"7586_CR38","first-page":"139","volume":"47","author":"M Siebert","year":"2021","unstructured":"Siebert M, Alyami M, Mercier F, Gallice C, Villeneuve L, Laplace N et al (2021) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 47(1):139\u2013142","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol."},{"issue":"12","key":"7586_CR39","first-page":"2386","volume":"45","author":"O Sgarbura","year":"2019","unstructured":"Sgarbura O, H\u00fcbner M, Alyami M, Eveno C, Gagni\u00e8re J, Pache B et al (2019) Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 45(12):2386\u20132391","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"6","key":"7586_CR40","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1007\/s00464-020-07488-6","volume":"34","author":"C Ceribelli","year":"2020","unstructured":"Ceribelli C, Debs T, Chevallier A, Piche MA, Bereder JM (2020) Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center. Surg Endosc 34(6):2803\u20132806","journal-title":"Surg Endosc"},{"issue":"5","key":"7586_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/biomedicines8050102","volume":"8","author":"M De Simone","year":"2020","unstructured":"De Simone M, Vaira M, Argenziano M, Berchialla P, Pisacane A, Cinquegrana A et al (2020) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, phase II clinical trial. Biomedicines 8(5):102","journal-title":"Biomedicines"},{"issue":"1","key":"7586_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12957-021-02357-5","volume":"19","author":"R Ra\u010dkauskas","year":"2021","unstructured":"Ra\u010dkauskas R, Bau\u0161ys A, Luk\u0161ta M, Jurgaitis J, Pa\u0161konis M, Strupas K (2021) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries. World J Surg Oncol 19(1):236","journal-title":"World J Surg Oncol"},{"key":"7586_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/6852749","volume":"2017","author":"M H\u00fcbner","year":"2017","unstructured":"H\u00fcbner M, Teixeira Farinha H, Grass F, Wolfer A, Mathevet P, Hahnloser D et al (2017) Feasibility and safety of pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract 2017:1\u20137","journal-title":"Gastroenterol Res Pract"},{"key":"7586_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29337\/ijsonco.131","volume":"7","author":"S Mehta","year":"2022","unstructured":"Mehta S, Kammar P, Patel A, Goswami G, Shaikh S, Sukumar V et al (2022) Feasibility and safety of taxane-PIPAC in patients with peritoneal malignancies-a retrospective bi-institutional study. Indian J Surg Oncol 7:1\u20139","journal-title":"Indian J Surg Oncol"},{"issue":"2","key":"7586_CR45","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1245\/s10434-023-14648-0","volume":"31","author":"G Vizzielli","year":"2023","unstructured":"Vizzielli G, Giudice MT, Nardelli F, Costantini B, Salutari V, Inzani FS et al (2023) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (ID: PARROT trial). Ann Surg Oncol 31(2):1207\u20131216","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"7586_CR46","volume":"49","author":"C Taliento","year":"2023","unstructured":"Taliento C, Restaino S, Scutiero G, Arcieri M, Bernardi G, Martinello R et al (2023) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: a systematic review. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 49(12):107250","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"5","key":"7586_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4(5):277\u2013283","journal-title":"Lancet Oncol"},{"issue":"2","key":"7586_CR48","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","volume":"20","author":"G Nadiradze","year":"2016","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg Off J Soc Surg Aliment Tract 20(2):367\u2013373","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"issue":"1","key":"7586_CR49","first-page":"123","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G et al (2021) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 47(1):123\u2013127","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"9","key":"7586_CR50","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J et al (2017) Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 3(9):1237\u20131244","journal-title":"JAMA Oncol"},{"issue":"12","key":"7586_CR51","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT et al (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 17(12):1709\u20131719","journal-title":"Lancet Oncol"},{"issue":"12","key":"7586_CR52","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","volume":"21","author":"JT Miura","year":"2014","unstructured":"Miura JT, Johnston FM, Gamblin TC, Turaga KK (2014) Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol 21(12):3947\u20133953","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7586_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","volume":"14","author":"R Girshally","year":"2016","unstructured":"Girshally R, Demtr\u00f6der C, Albayrak N, Zieren J, Tempfer C, Reymond MA (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 14(1):253","journal-title":"World J Surg Oncol"},{"issue":"12","key":"7586_CR54","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11605-018-3916-5","volume":"22","author":"U Giger-Pabst","year":"2018","unstructured":"Giger-Pabst U, Tempfer CB (2018) How to perform safe and technically optimized pressurized intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200 procedures. J Gastrointest Surg 22(12):2187\u20132193","journal-title":"J Gastrointest Surg"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07586-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-024-07586-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07586-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T04:23:44Z","timestamp":1726115024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-024-07586-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["7586"],"URL":"https:\/\/doi.org\/10.1007\/s00404-024-07586-z","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No relevant conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}